Literature DB >> 1815971

Absolute bioavailability of nicotine applied to different nasal regions.

C J Johansson1, P Olsson, M Bende, T Carlsson, P O Gunnarsson.   

Abstract

The absolute bioavailability of nicotine administered nasally, as drops to the nasal conchae and nasal septum, and as a nasal spray, has been studied in eight healthy volunteers. Single nasal doses of 1 mg nicotine were given and plasma concentrations of nicotine were followed for 6 h. Compared to an intravenous infusion of nicotine, the bioavailability of the nasal administrations was 60 to 75%. The rate of absorption was fast, the maximum concentration being reached after about 10 min. In the present study, there was no significant difference in the rate or extent of absorption between the different nasal treatments.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815971     DOI: 10.1007/BF00314989

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  The administration of drugs and vaccines by the intranasal route.

Authors:  D S Freestone; A L Weinberg
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

2.  Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity.

Authors:  C McMartin; L E Hutchinson; R Hyde; G E Peters
Journal:  J Pharm Sci       Date:  1987-07       Impact factor: 3.534

3.  Intranasal drug delivery by spray and drops.

Authors:  J G Hardy; S W Lee; C G Wilson
Journal:  J Pharm Pharmacol       Date:  1985-05       Impact factor: 3.765

4.  Nasal nicotine solution: a potential aid to giving up smoking?

Authors:  M A Russell; M J Jarvis; C Feyerabend; O Fernö
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-26

5.  Interindividual variability in the metabolism and cardiovascular effects of nicotine in man.

Authors:  N L Benowitz; P Jacob; R T Jones; J Rosenberg
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

6.  Nasal absorption of propranolol in humans.

Authors:  A Hussain; T Foster; S Hirai; T Kashihara; R Batenhorst; M Jones
Journal:  J Pharm Sci       Date:  1980-10       Impact factor: 3.534

7.  Plasma nicotine concentrations from repeated doses of nasal nicotine solution.

Authors:  R J West; M J Jarvis; M A Russell; C Feyerabend
Journal:  Br J Addict       Date:  1984-12

8.  Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin.

Authors:  A S Harris; I M Nilsson; Z G Wagner; U Alkner
Journal:  J Pharm Sci       Date:  1986-11       Impact factor: 3.534

9.  Distribution and clearance of radioactive aerosol on the nasal mucosa.

Authors:  J A McLean; J R Bacon; K P Mathews; J H Thrall; J M Banas; J Hedden; N K Bayne
Journal:  Rhinology       Date:  1984-03       Impact factor: 3.681

10.  Daily intake of nicotine during cigarette smoking.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1984-04       Impact factor: 6.875

View more
  12 in total

1.  Nasal nicotine spray: a rapid nicotine delivery system.

Authors:  G Sutherland; M A Russell; J Stapleton; C Feyerabend; O Ferno
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems.

Authors:  N G Schneider; E Lunell; R E Olmstead; K O Fagerström
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

3.  Therapeutic advances in the treatment of nicotine addiction: present and future.

Authors:  Giuseppina Casella; Pasquale Caponnetto; Riccardo Polosa
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

Review 4.  Treatment of nicotine addiction: present therapeutic options and pipeline developments.

Authors:  Riccardo Polosa; Neal L Benowitz
Journal:  Trends Pharmacol Sci       Date:  2011-01-20       Impact factor: 14.819

Review 5.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Nicotine chemistry, metabolism, kinetics and biomarkers.

Authors:  Neal L Benowitz; Janne Hukkanen; Peyton Jacob
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients.

Authors:  L Elliot Hong; Ikwunga Wonodi; Jada Lewis; Gunvant K Thaker
Journal:  Neuropsychopharmacology       Date:  2007-10-24       Impact factor: 7.853

8.  Initial nicotine sensitivity in humans as a function of impulsivity.

Authors:  Kenneth A Perkins; Caryn Lerman; Sarah B Coddington; Christopher Jetton; Joshua L Karelitz; John A Scott; Annette S Wilson
Journal:  Psychopharmacology (Berl)       Date:  2008-07-05       Impact factor: 4.530

Review 9.  [Smoking cessation with nicotine replacement therapy (NRT) - a scientific update].

Authors:  Karl-Heinz Mulzer; Alfred Lichtenschopf; Irmgard Homeier; Ernest Groman
Journal:  Wien Med Wochenschr       Date:  2009

Review 10.  Guidelines on nicotine dose selection for in vivo research.

Authors:  Shannon G Matta; David J Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward D Levin; Ronald J Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.